129 related articles for article (PubMed ID: 12480736)
1. Molecular and functional dissection of TGF-beta1-induced cerebrovascular abnormalities in transgenic mice.
Buckwalter M; Pepper JP; Gaertner RF; Von Euw D; Lacombe P; Wyss-Coray T
Ann N Y Acad Sci; 2002 Nov; 977():87-95. PubMed ID: 12480736
[TBL] [Abstract][Full Text] [Related]
2. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice.
Wyss-Coray T; Lin C; Sanan DA; Mucke L; Masliah E
Am J Pathol; 2000 Jan; 156(1):139-50. PubMed ID: 10623661
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease-like cerebrovascular pathology in transforming growth factor-beta 1 transgenic mice and functional metabolic correlates.
Wyss-Coray T; Lin C; von Euw D; Masliah E; Mucke L; Lacombe P
Ann N Y Acad Sci; 2000 Apr; 903():317-23. PubMed ID: 10818521
[TBL] [Abstract][Full Text] [Related]
4. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease.
Wyss-Coray T; Masliah E; Mallory M; McConlogue L; Johnson-Wood K; Lin C; Mucke L
Nature; 1997 Oct; 389(6651):603-6. PubMed ID: 9335500
[TBL] [Abstract][Full Text] [Related]
5. Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease.
Ongali B; Nicolakakis N; Lecrux C; Aboulkassim T; Rosa-Neto P; Papadopoulos P; Tong XK; Hamel E
Am J Pathol; 2010 Dec; 177(6):3071-80. PubMed ID: 21088218
[TBL] [Abstract][Full Text] [Related]
6. Cerebrovascular pathology during the progression of experimental Alzheimer's disease.
Giannoni P; Arango-Lievano M; Neves ID; Rousset MC; Baranger K; Rivera S; Jeanneteau F; Claeysen S; Marchi N
Neurobiol Dis; 2016 Apr; 88():107-17. PubMed ID: 26774030
[TBL] [Abstract][Full Text] [Related]
7. Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities.
Gaertner RF; Wyss-Coray T; Von Euw D; Lesné S; Vivien D; Lacombe P
Neurobiol Dis; 2005; 19(1-2):38-46. PubMed ID: 15837559
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.
Wyss-Coray T; Lin C; Yan F; Yu GQ; Rohde M; McConlogue L; Masliah E; Mucke L
Nat Med; 2001 May; 7(5):612-8. PubMed ID: 11329064
[TBL] [Abstract][Full Text] [Related]
9. TGF-β1 affects endothelial cell interaction with macrophages and T cells leading to the development of cerebrovascular amyloidosis.
Weiss R; Lifshitz V; Frenkel D
Brain Behav Immun; 2011 Jul; 25(5):1017-24. PubMed ID: 21112386
[TBL] [Abstract][Full Text] [Related]
10. TGF-β1 factor in the cerebrovascular diseases of Alzheimer's disease.
Zhang X; Huang WJ; Chen WW
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5178-5185. PubMed ID: 28051272
[TBL] [Abstract][Full Text] [Related]
11. Association of a polymorphism of the transforming growth factor-beta1 gene with cerebral amyloid angiopathy.
Hamaguchi T; Okino S; Sodeyama N; Itoh Y; Takahashi A; Otomo E; Matsushita M; Mizusawa H; Yamada M
J Neurol Neurosurg Psychiatry; 2005 May; 76(5):696-9. PubMed ID: 15834029
[TBL] [Abstract][Full Text] [Related]
12. Cerebral circulation: function and dysfunction in Alzheimer's disease.
Hamel E
J Cardiovasc Pharmacol; 2015 Apr; 65(4):317-24. PubMed ID: 25384195
[TBL] [Abstract][Full Text] [Related]
13. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein.
Niwa K; Kazama K; Younkin SG; Carlson GA; Iadecola C
Neurobiol Dis; 2002 Feb; 9(1):61-8. PubMed ID: 11848685
[TBL] [Abstract][Full Text] [Related]
14. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease.
Tong XK; Nicolakakis N; Kocharyan A; Hamel E
J Neurosci; 2005 Nov; 25(48):11165-74. PubMed ID: 16319316
[TBL] [Abstract][Full Text] [Related]
15. Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy.
Saito S; Yamamoto Y; Maki T; Hattori Y; Ito H; Mizuno K; Harada-Shiba M; Kalaria RN; Fukushima M; Takahashi R; Ihara M
Acta Neuropathol Commun; 2017 Apr; 5(1):26. PubMed ID: 28376923
[TBL] [Abstract][Full Text] [Related]
16. Selective in vivo antagonism of endothelin receptors in transforming growth factor-beta1 transgenic mice that mimic the vascular pathology of Alzheimer's disease.
Papadopoulos P; Ongali B; Hamel E
Can J Physiol Pharmacol; 2010 Jun; 88(6):652-60. PubMed ID: 20628431
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models.
Burgermeister P; Calhoun ME; Winkler DT; Jucker M
Ann N Y Acad Sci; 2000 Apr; 903():307-16. PubMed ID: 10818520
[TBL] [Abstract][Full Text] [Related]
18. Losartan improves cerebrovascular function in a mouse model of Alzheimer's disease with combined overproduction of amyloid-β and transforming growth factor-β1.
Papadopoulos P; Tong XK; Imboden H; Hamel E
J Cereb Blood Flow Metab; 2017 Jun; 37(6):1959-1970. PubMed ID: 27389178
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin.
Rockenstein E; Adame A; Mante M; Larrea G; Crews L; Windisch M; Moessler H; Masliah E
J Neural Transm (Vienna); 2005 Feb; 112(2):269-82. PubMed ID: 15657642
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta 1 impairs endothelin-1-mediated contraction of brain vessels by inducing mitogen-activated protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase.
Tong XK; Hamel E
Mol Pharmacol; 2007 Dec; 72(6):1476-83. PubMed ID: 17848599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
